'김갑성' 기자의 전체기사
-
Real-World Evidence of NEFECON® to Be Presented in Seven Ne…
7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Nephropathy Symposium (IIgANN 2025). The newly released results, based on clinical practices at several leading hospitals in China, offer a comprehensive overview of the efficacy and safety of NEFECON® in the treatment of IgA nephropathy (IgAN). NEFECON® clinical value was highlighted across three key dimensions, consistent with the new disease management strategy of "Treat the cause, Treat early, Treat long-term." NEFECON® is currently the only etiological treatment for
- 김갑성 기자
- 2025-09-15 07:45
-
Ispire Technology Inc. Schedules Fiscal Fourth Quarter an…
LOS ANGELES, Sept. 13, 2025 -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Tuesday, September 16, 2025, to discuss the Company's financial results for its fiscal fourth quarter and full year ended June 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Tuesday, September 16
- 김갑성 기자
- 2025-09-13 04:05
-
WFH mobilizes global community to achieve milestone revisio…
MONTREAL, Sept. 12, 2025 -- A concerted effort by the World Federation of Hemophilia (WFH) and its partners has led to the World Health Organization (WHO) updating its Essential Medicines List (EML) and the Essential Medicines List for Children (EMLc) to better align the EMLs to the international clinical guidelines for the management of hemophilia and von Willebrand Disease (VWD). These revisions will have a positive impact on lives of people with bleeding disorders (PWBDs) everywhere. The WHO EML has a critical role in guiding national governments on the selection and financi
- 김갑성 기자
- 2025-09-12 21:42
-
LakeShore Biopharma Announces Receipt of Delisting Dete…
BEIJING, Sept. 12, 2025 -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it received a staff determination letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), dated September 11, 2025, notifying that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price R
- 김갑성 기자
- 2025-09-12 20:00
-
Pulnovo Medical Receives two IDE approvals for PADN system's…
SHANGHAI, Sept. 12, 2025 -- Pulnovo Medical, a globally recognized leader in medical devices for pulmonary hypertension (PH) and heart failure (HF), is proud to announce that its PADN catheter and generator has received two Investigational Device Exemption (IDE) approvals—HDE study approved for patients with Group I PH patients, PMA study approved for patients with Group II PH patients, with CMS full coverage approval, paving the way for upcoming clinical trials in the United States. Following the FDA's BDD designation granted in 2021 for Groups I, II, and IV, the newly obtained IDE ap
- 김갑성 기자
- 2025-09-12 18:23
-
건선 질환, 유엔 총회에서 주요 의제로 부상: IFPA, 유엔 고위급 회의에서 건선 질환에 대한…
스톡홀름, 2025년 9월 12일 -- 국제건선협회연맹(국제 건선 협회 연맹(International Federation of Psoriasis Associations, IFPA)이 오는 뉴욕 제80차 UN 총회(UNGA 80)에서 건선 질환을 조명한다고 밝혔다. 이번 총회에서는 세계 각국 지도자들이 비감염성 질환(NCD), 정신 건강 및 웰빙과 관련하여 새로운 정치적 선언문을 채택할 예정이다. 주요 내용: 전 세계 약 6000만 명이 건선 질환을 앓고 있으며, 이는 피부, 관절, 기타 장기를 침범하는 심각하고 평생 지속되는 비감염성 질환이다. 건선은 또한 당뇨병, 비만, 심혈관 질환 및 우울증의 위험을 높인다. 2014년 세계보건기구(WHO)가 건선을 주요 공중 보건 문제로 인정한 결의안을 채택했음에도 불구하고, 관련 진행은 더디게 이루어지고 있다. 이에 IFPA는 새로운 글로벌 차원의 노력을 촉구하고 있다. IFPA 대표단은 UN 고위급 NCD 회의에 참석해 건선 질환을 글로벌•국가 보건 정책에 포함시키고, 특히 실제 경험을 정책 결정의 중심에 두도록 촉구
- 김갑성 기자
- 2025-09-12 17:25
-
3Shape Announces Leadership Transition: Rune Fisker A…
COPENHAGEN, Denmark, Sept. 12, 2025 -- 3Shape today announced a leadership transition that honors one of its most influential innovators. After 25 years at the forefront of 3Shape's journey, Rune Fisker, Senior Vice President of Product Strategy, will step down from his current role and transition into a new position as External Executive Advisor to CEO Jacob Paulsen. Since joining 3Shape at its earliest stages, Rune has been synonymous with innovation, vision, and growth. From laying the foundation of 3Shape's groundbreaking scanner development to driving the company's product organiz
- 김갑성 기자
- 2025-09-12 15:47
-
Nexus Aesthetic Clinic Founder Dr. Samantha Tay Advocates…
[ 메디채널 김갑성 기자 ] Founder of Nexus Aesthetic Clinic addresses public concerns about injectables and highlights the importance of professional oversight. SINGAPORE, Sept. 12, 2025 -- Amid a growing public conversation about the safety and efficacy of aesthetic procedures, Dr. Samantha Tay, founder of Nexus Aesthetic Clinic, is emphasizing the importance of prioritizing patient safety through direct, doctor-led care. By personally conducting all patient consultations and administering all injectable treatments, Dr. Tay aims to provide a transparent and reassuring experience for individua
- 김갑성 기자
- 2025-09-12 15:08
-
Prioritizing Quality and Patient Safety with Digital Transformation…
[ 메디채널 김갑성 기자 ] Setting new standards in healthcare quality and patient safety through digital transformation. JAKARTA, Indonesia, Sept. 12, 2025 -- RS Pondok Indah Group (Pondok Indah Hospital Group) has made history as the first hospital group in Indonesia to achieve the HIMSS Electronic Medical Record Adoption Model (EMRAM) Stage 7, the world's highest quality standard for assessing digital maturity and data management in hospitals. This recognition was awarded to all three hospitals under RS Pondok Indah Group—RS Pondok Indah – Pondok Indah, RS Pondok Indah – Puri Indah, and RS P
- 김갑성 기자
- 2025-09-12 14:14
-
Indication Expansion Accelerates: First Patient Dosed in Me…
NANJING, China, Sept. 12, 2025 -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamtistomig (LBL-024, PD-L1/4-1BB bispecific antibody) as monotherapy or in combination with other agents for the first-line treatment of advanced melanoma. Opamtistomig, a uniquely designed PD-L1/4-1BB bispecific antibody that simultaneously blocks PD-1/L1-mediated immune suppression and enhances 4-1BB-regulated T-cell acti
- 김갑성 기자
- 2025-09-12 12:39
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 16시 40분